title: Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancer.
abstract: Brain metastasis from non-small cell lung cancer remains a challenge to physicians. It occurs in 30% of patients with advanced stage adenocarcinoma of lung and is often regarded as the ominous sign of disease progression and death. Alectinib is likely to be a promising agent, even after the failure of crizotinib and ceritinib, for patients with anaplastic lymphoma kinase (ALK) -driven non-small cell lung cancer with brain metastasis, resulting in a durable response for both intracranial and extra-cranial diseases.
authors.affiliation: Department of Medicine Queen Mary Hospital Hong Kong China.
authors.forename: Wang Chun
authors.identifier: 0000-0002-5611-1637
authors.initials: WC
authors.lastname: Kwok
authors.affiliation: Department of Medicine Queen Mary Hospital Hong Kong China.
authors.forename: Terence Chi Chun
authors.initials: TC
authors.lastname: Tam
authors.affiliation: Department of Medicine Queen Mary Hospital Hong Kong China.
authors.forename: Macy Mei Sze
authors.initials: MM
authors.lastname: Lui
authors.affiliation: Department of Medicine Queen Mary Hospital Hong Kong China.
authors.forename: David Chi Leung
authors.initials: DC
authors.lastname: Lam
authors.affiliation: Department of Medicine Queen Mary Hospital Hong Kong China.
authors.forename: James Chung Man
authors.identifier: 0000-0003-4499-5284
authors.initials: JC
authors.lastname: Ho
keywords: Alectinib; anaplastic lymphoma kinase; brain metastasis; lung cancer; tyrosine kinase inhibitor